- Trials with a EudraCT protocol (96)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
96 result(s) found for: Left atrial volume.
Displaying page 1 of 5.
EudraCT Number: 2013-000797-30 | Sponsor Protocol Number: SPI-IIT-002 | Start Date*: 2013-10-08 | |||||||||||||||||||||
Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital | |||||||||||||||||||||||
Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation | |||||||||||||||||||||||
Medical condition: Paroxysmal and persistent atrial fibrillation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000442-18 | Sponsor Protocol Number: ABM/2020/1/00002 | Start Date*: 2021-09-24 | ||||||||||||||||
Sponsor Name:National Institute of Cardiology | ||||||||||||||||||
Full Title: Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial) | ||||||||||||||||||
Medical condition: Mitral regurgitation Atrial fibrilation Periprocedural anticoagulation strategy in patients treated with MitraClip implantation or Left Atrial Appendage Closure. The patients scheduled for Mitr... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003487-48 | Sponsor Protocol Number: F373280CA201 | Start Date*: 2013-02-25 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure. | |||||||||||||
Medical condition: F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic h... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) CZ (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002928-53 | Sponsor Protocol Number: HBT-GCP-PTCL-01 | Start Date*: 2015-11-16 |
Sponsor Name:The Heartbeat Trust | ||
Full Title: Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) | ||
Medical condition: Patients (asymptomatic) with cardiovascular risk factors for heart failure including either hypertension and/or type II diabetes, with elevated levels of natriuretic peptide (brain natriuretic pept... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002541-11 | Sponsor Protocol Number: P170912J | Start Date*: 2019-06-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002532-12 | Sponsor Protocol Number: IDE:G050233 | Start Date*: 2011-10-27 | |||||||||||
Sponsor Name:MAYO CLINIC | |||||||||||||
Full Title: Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA) | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003820-58 | Sponsor Protocol Number: D1690C00063 | Start Date*: 2018-02-08 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 d... | ||
Medical condition: type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006123-37 | Sponsor Protocol Number: SI-C-019 | Start Date*: 2012-06-06 | |||||||||||
Sponsor Name:Solvotrin Innovations Ltd | |||||||||||||
Full Title: Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients | |||||||||||||
Medical condition: Asymptomatic left ventricular diastolic dysfunction in diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011006-42 | Sponsor Protocol Number: vs.3.23-02-2009 | Start Date*: 2009-07-13 | ||||||||||||||||
Sponsor Name:Rigshospitalet, Hjertemedicinsk afd. B | ||||||||||||||||||
Full Title: Sildenafil and diastolic dysfunction after AMI | ||||||||||||||||||
Medical condition: Diastolic dysfunction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001930-34 | Sponsor Protocol Number: 170674-3479 | Start Date*: 2005-11-25 |
Sponsor Name:Department of Cardiology, Odense University Hospital | ||
Full Title: Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor | ||
Medical condition: Patients with severe aortic valve stenosis treated with Aortic Valve Replacement (AVR) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003688-37 | Sponsor Protocol Number: KKS-243 | Start Date*: 2018-07-06 | ||||||||||||||||
Sponsor Name:Philipps-Universität Marburg | ||||||||||||||||||
Full Title: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controll... | ||||||||||||||||||
Medical condition: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002020-25 | Sponsor Protocol Number: 052017 | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: ANGIOTENSIN–NEPRILYSIN INHIBITION IN DIASTOLIC DYSFUNCTION AFTER AMI | |||||||||||||
Medical condition: Diastolic dysfunction after acute myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000481-14 | Sponsor Protocol Number: APHP210166 | Start Date*: 2021-12-20 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Cardiometabolic effects of dapagliflozin in heart failure with reduced ejection fraction: an exploratory study. | ||
Medical condition: Heart failure with reduced ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005844-47 | Sponsor Protocol Number: D6580C00010 | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit... | |||||||||||||
Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed) HU (Completed) PL (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005317-40 | Sponsor Protocol Number: Herlev | Start Date*: 2021-05-27 |
Sponsor Name:Odense University Hospital - Department of Cardiology | ||
Full Title: Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): A randomized controlled trial | ||
Medical condition: Obese patients (BMI >28 kg/m2), aged 60-84 years, with documented cardiovascular disease but no history of diabetes mellitus or heart failure with reduced ejection fraction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000733-14 | Sponsor Protocol Number: DAPA-HD | Start Date*: 2022-07-18 |
Sponsor Name:Medical University of Vienna | ||
Full Title: SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL | ||
Medical condition: Cardiovascular Outcome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022820-61 | Sponsor Protocol Number: Tad-10 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: PHASE CONTRAST MAGNETIC RESONANCE (MR) IMAGING IN MONITORING THE EFFECTS OF TADALAFIL IN PATIENTS WITH OUT-OF-PROPORTION PULMONARY HYPERTENSION AND LEFT VENTRICULAR DYSFUNCTION | |||||||||||||
Medical condition: Pulmonary Hypertension ``out-of-proportion`` associated to moderate left ventricular dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005724-10 | Sponsor Protocol Number: SPIHF-201 | Start Date*: 2016-06-07 | |||||||||||
Sponsor Name:Stealth BioTherapeutics Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart... | |||||||||||||
Medical condition: Stable Heart Failure with Reduced Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002558-21 | Sponsor Protocol Number: AT-001-2001 | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:Applied Therapeutics Inc. | |||||||||||||
Full Title: Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in ... | |||||||||||||
Medical condition: Diabetic Cardiomyopathy (DbCM) / Stage B Heart Failure (SBHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002288-25 | Sponsor Protocol Number: BAY1021189/15829 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
